cstnprapp12.centerstone.lan
Home / Depression / Ketamine/Esketamine Program for Treatment-Resistant Depression

Ketamine/Esketamine Program for Treatment-Resistant Depression

Centerstone has begun a new therapy program for individuals seeking treatment for severe depression at our Florida location.

About the Program

We are now certified to offer Spravato, a nasal spray that contains the FDA-approved medication Esketamine, and ketamine infusion therapy for people who have been treated for depression with no improvement in symptoms.

Both Spravato and ketamine infusion therapy are administered under the supervision of a medical professional, and patients are required to complete a comprehensive screening with a Centerstone physician prior to receiving treatment. Ketamine infusion therapy lasts approximately four hours for each dosage; Esketamine treatment takes approximately two hours.

Screenings and treatments are scheduled at our Bradenton, Fla., locations.

Patient Support

The Johnson & Johnson Patient Assistance Foundation Inc. (JJPAF) is an independent, nonprofit organization committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. For more information, visit jjpaf.org.

Once Spravato has been prescribed, Janssen CarePath can help you find the resources you may need to help get started on the medication and stay on track. For more information, visit janssencarepath.com.

Frequently Asked Questions

What are Ketamine and Esketamine?

  • Ketamine is a medication traditionally used for anesthesia during surgery that was approved for use in the United States in 1970. While it does have a history as a drug of abuse, it is a safe and valuable medication when properly administered by a trained medical professional.
  • Esketamine was introduced as an anesthetic in Germany in 1997 and was then marketed in other countries. It is part of ketamine but differs slightly on a molecular level.

How long have they been used to treat depression?

  • For the past decade or so, researchers began studying the use of ketamine as an application for Treatment-Resistant Depression (TRD). Studies indicated that ketamine was highly successful at reducing symptoms of depression; some indicated relief of symptoms in about 80% of people prescribed. Despite their molecular differences, ketamine and Esketamine act essentially the same in their uses and effectiveness for treating TRD. Esketamine was approved by the U.S. Food and Drug Administration (FDA) in March 2019 under the drug name SpravatoTM.

When should Esketamine be considered for use?

  • Esketamine is approved to treat Treatment-Resistant Depression, which is diagnosed in patients who have suffered at least one major depressive episode and have experienced at least two failed drug therapies.

How is Esketamine used in treatment?

  • Spravato (Esketamine) is a fast-acting nasal spray approved for use in conjunction with an oral antidepressant in adults with Treatment-Resistant Depression.

How long does the treatment take?

  • For Esketamine administration, patients will need
    • 2 treatments per week for the first month (8 total)
    • 1 treatment per week for the second month (4 total)
    • 1 treatment every two weeks for the third month (2 total)
  • The initial visit will take about 2 hours; each subsequent appointment will take about 3 hours each.

Does insurance cover treatment costs?

  • Your insurance provider may cover Esketamine or Spravato. By enrolling in Janssen CarePath, you can receive guidance on submitting claims so that Spravato can be considered under your pharmacy benefits.

Do I need a referral before seeking treatment?

  • If you think Esketamine may be a good fit for you, it is a good idea to talk with your health care provider, but a referral by a medical professional is not required.

When can I expect to see results?

  • Patients typically begin to feel the effects within a few hours of treatment to the day after treatment. If the treatment schedule is adhered to, most patients will continue to feel the effects for up to several months.

For More Information

To learn more about the Spravato nasal spray, including answers to frequently asked questions, go online to spravato.com.

In the News

To see a report from WFLA-TV about this program, click here.

Call Today

For more information about Spravato self-pay rates, ketamine infusion therapy and Centerstone’s depression care services or to make an appointment, call (941) 782-4610.


Related Posts

Depression

Register Now for Life;Story Run/Walk

This event has passed. Centerstone’s 17th annual Life;Story Run/Walk will be held Saturday, Sept. 21, 2019 at 7:30 a.m. at Nathan Benderson Park in Sarasota, Fla.   Centerstone’s Life;Story 5K/10K is an annual event to increase depression awareness while sharing the message that suicide can be prevented. “We are losing more than 40,000 people to ...

No image set - Centerstone logo
Kentucky

Positive Treatment Outcomes at Addiction Recovery Center

The following report describes outcomes for 73 clients who participated in the treatment programs at Centerstone Addiction Recovery Center.  Patients responded to survey questions at initial intake and at their 1 year follow-up. Click on the infographic below to enlarge it.   ...

Indiana

Present at National Conferences

Centerstone’s Jason Turi, Maren Sheese, Lindsay Potts and Kimberly Brothers recently presented at national conferences about integrated care initiatives and innovations. These conferences and presentations represented integrated behavioral health needs to a broad audience. Putting Care at the Center is a national conference sponsored by the Camden Coalition and the National Center for Complex Health ...

Research Institute

Centerstone Research At 2018 American Evaluation Conference

In early November, 13 Centerstone Research Institute staff attended the 2018 American Evaluation Association (AEA) Conference in Cleveland, OH. Over 3,000 AEA members attended the conference in person; 1,106 attended virtually from across the globe. The conference theme was based upon a very old phrase with significant relevance for today’s professional evaluator, speaking truth to power. Evaluators were encouraged to speak truth to power in the course of their daily practice. ...

Gambling

Centerstone gambling symposium highlights need for treatment services in Southern Illinois

MARION, Ill. – Centerstone recently hosted the Problem and Compulsive Gambling Symposium at The Pavilion in Marion. “We wanted to host this symposium to highlight the need for gambling treatment services in our region,” said Angela Quigley-Ragland, clinical coordinator at Centerstone. “We need to educate the community so we can all support those with gambling ...

No image set - Centerstone logo

Melissa Larkin-Skinner appointed to Statewide Council on Human Trafficking in Florida

Melissa Larkin-Skinner, regional CEO in Florida, has been named to the Direct Support Organization for the Statewide Council on Human Trafficking by Florida House Speaker Jose R. Oliva. A licensed mental health counselor with 25 years of experience in mental health and addiction prevention and treatment, Melissa has worked with children and adults of all ...

No image set - Centerstone logo
Indiana

Centerstone Receives More Than $220,000 to Support Programs in Indiana

Centerstone received over $220,000 in grants and donations supporting special programming across Indiana from July to September 2019. The Community Foundation of Louisville funded materials for Centerstone’s family support specialist at Slate Run Elementary School in Floyd County. Materials included art supplies and small toys to help children who have experienced trauma with a way ...

Florida

Roger Johnson Promoted to CAO for Centerstone Florida

Melissa Larkin-Skinner, Chief Executive Officer at Centerstone Florida, recently announced the promotion of Roger Johnson to Chief Administrative Officer. Johnson previously served as Senior Vice President of Medical Services and Managed Care. In his new role, Johnson will take on additional responsibilities for leading and promoting growth for Centerstone’s medical records and facilities. Since joining ...

No image set - Centerstone logo
Indiana

Columbus Homeless Outreach Program (CHOP) Sees Continued Success

Centerstone’s Columbus Homeless Outreach Project (CHOP) is in the middle of a successful fourth year, thanks in large part to generous, multi-year support from the Columbus Regional Health Foundation, Heritage Fund and City of Columbus Community Development Block Grant (CDBG). Since its inception in Fall 2014, CHOP has assisted nearly 250 individuals and families with finding ...